Literature DB >> 1645740

A toxin-resistant mouse L-cell mutant defective in protein transport along the secretory pathway.

S M Laurie1, A R Robbins.   

Abstract

Using methods designed for isolation of mutants defective in receptor-mediated endocytosis, a novel L-cell mutant was obtained that exhibits resistance to three different protein toxins as well as alterations in secretion. This mutant, LEFIC, is resistant to modeccin, Pseudomonas exotoxin, and ricin. These toxins, which enter the cytoplasm via receptor-mediated endocytosis, are thought to penetrate into cells at the level of late endosomes or the trans Golgi network. Early endosomal acidification appears to be normal in the mutant based on its accumulation of iron from transferrin and its sensitivity to diphtheria toxin A chain-transferrin conjugate. Within the secretory pathway two delays in transport of vesicular stomatitis virus (VSV) G protein were observed in LEFIC: a 20-30 min delay in acquisition of Endo H resistance and a 1-2 hr delay in appearance of newly synthesized G protein on the cell surface. Movement of endogenous proteins along the secretory pathway was also affected in LEFIC. Fibronectin secretion was delayed by 15 min, and membrane proteins were delayed in arrival at the cell surface. The phenotype of LEFIC is consistent with a defect in a component or compartment shared by both the late endocytic and constitutive secretory pathways.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1645740     DOI: 10.1002/jcp.1041470205

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.513


  2 in total

1.  Disruptions in Golgi structure and membrane traffic in a conditional lethal mammalian cell mutant are corrected by epsilon-COP.

Authors:  Q Guo; E Vasile; M Krieger
Journal:  J Cell Biol       Date:  1994-06       Impact factor: 10.539

2.  Expression cloning of cDNAs that render cancer cells resistant to Pseudomonas and diphtheria toxin and immunotoxins.

Authors:  U Brinkmann; E Brinkmann; I Pastan
Journal:  Mol Med       Date:  1995-01       Impact factor: 6.376

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.